GlucoTrack (GCTK) Stock Price, News & Analysis

Company Overview

GlucoTrack, Inc., a medical device company, focused on the design, development, and commercialization of novel technologies for people with diabetes in the United States. It develops GlucoTrack, a noninvasive glucose monitoring device that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Rutherford, New Jersey.

Key Stats

• Today's Range: $0.19 to $0.22
• 50-Day Range: $0.21 to $2.50
• 52-Week Range: $0.19 to $99.00
• Volume: 2.27 million shs
• Average Volume: 1.53 million shs
• Market Capitalization: $2.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

GlucoTrack Stock Analysis - MarketRank™

GlucoTrack scored higher than 38% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for GlucoTrack.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of GlucoTrack is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of GlucoTrack is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

GlucoTrack has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.79% of the float of GlucoTrack has been sold short.

Short Interest Ratio / Days to Cover

GlucoTrack has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GlucoTrack has recently decreased by 63.94%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GlucoTrack does not currently pay a dividend.

Dividend Growth

GlucoTrack does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.79% of the float of GlucoTrack has been sold short.

Short Interest Ratio / Days to Cover

GlucoTrack has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GlucoTrack has recently decreased by 63.94%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 1.43

News Sentiment

GlucoTrack has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.80 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for GlucoTrack this week, compared to 1 article on an average week.

Search Interest

8 people have searched for GCTK on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GlucoTrack insiders have not sold or bought any company stock.

Percentage Held by Insiders

46.50% of the stock of GlucoTrack is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 10.92% of the stock of GlucoTrack is held by institutions.

GCTK Stock Analysis - Frequently Asked Questions

How have GCTK shares performed this year?

GlucoTrack's stock was trading at $7.46 at the beginning of the year. Since then, GCTK shares have decreased by 97.3% and is now trading at $0.2050.
View the best growth stocks for 2025 here.

When did GlucoTrack's stock split?

GlucoTrack's stock reverse split on Tuesday, February 4th 2025. The 1-20 reverse split was announced on Thursday, January 30th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 3rd 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are GlucoTrack's major shareholders?

GlucoTrack's top institutional shareholders include Geode Capital Management LLC (14.10%) and XTX Topco Ltd (10.63%).
View institutional ownership trends.

How do I buy shares of GlucoTrack?

Shares of GCTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of GlucoTrack own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GlucoTrack investors own include Rolls-Royce Holdings plc (RYCEY), Blink Charging (BLNK), Cameco (CCJ), Cybin (CYBN), Cyclo Therapeutics (CYTH), Ford Motor (F) and iShares U.S. Infrastructure ETF (IFRA).

Company Calendar

• Today: 3/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:GCTK
• CIK: 1506983
• Web: www.glucotrack.com
• Phone: (201) 842-7715
• Fax: 972-8675-7850
• Employees: 5
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($56.60)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-7,100,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -826.43%
• Return on Assets: -707.26%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.14
• Quick Ratio: 0.14

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $15.30 per share
• Price / Book: 0.01

Miscellaneous

• Outstanding Shares: 10,413,000
• Free Float: 5,571,000
• Market Cap: $2.13 million
• Optionable: Not Optionable
• Beta: -0.29